| 001 | 1052252 | ||
| 005 | 20260122203308.0 | ||
| 024 | 7 | _ | |a 10.1093/neuonc/noaf009 |2 doi |
| 024 | 7 | _ | |a 1522-8517 |2 ISSN |
| 024 | 7 | _ | |a 1523-5866 |2 ISSN |
| 024 | 7 | _ | |a 10.34734/FZJ-2026-00869 |2 datacite_doi |
| 037 | _ | _ | |a FZJ-2026-00869 |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Kotecha, Rupesh |0 P:(DE-HGF)0 |b 0 |e Corresponding author |
| 245 | _ | _ | |a Benchmarking the efficacy of salvage systemic therapies for recurrent meningioma: A RANO group systematic review and meta-analysis to guide clinical trial design |
| 260 | _ | _ | |a Oxford |c 2025 |b Oxford Univ. Press |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1769088395_20964 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 500 | _ | _ | |a Neuro Oncol . 2025 Sep 8;27(7):1670-1685.Funding: none declared |
| 520 | _ | _ | |a Background. Despite advances in our understanding of the molecular underpinnings of meningioma progressionand innovations in systemic and local treatments, recurrent meningiomas remain a substantial therapeutic challenge.The objective of this systematic review and meta-analysis is to provide a historical baseline, contemporaryanalysis, and propose a “rate of probable interest” to inform future clinical trial design and development on behalfof the Response Assessment in Neuro-Oncology meningioma group.Methods. PubMed, ClinicalTrials.gov, and ASCOpubs databases were screened for clinical trials evaluating theactivity of systemic therapies for adults with recurrent meningiomas. The pooled progression-free survival at6-months and 1-year (PFS-6 and PFS-1 year) values were calculated using the random effects technique withI2 indices.Results. The pooled PFS-6 and PFS-1 year rates for recurrent WHO grade 1 meningiomas were 43.6% (95% CI:22.7-67.0%, I2 = 80%) and 21.7% (95% CI: 6.2-53.9%, I2 = 76%), and for grades 2-3 meningiomas, the PFS-6 was 38.0%(95% CI: 28.3-48.8%, I2 = 68%). In the targeted therapy group, PFS-6 and PFS-1 year rates stood at 62.0% (I2 = 58%)and 49.0% (I2 = 63%) for grade 1, while for grades 2-3 tumors, the PFS-6 rates with targeted therapy and immunotherapywere 42.1% (I² = 60%) and 46.0% (I² = 0%), respectively. The benchmarks were set at 67% and 54% for PFS-6and PFS-1 year for grade 1 tumors, and PFS-6 of 49% for grades 2-3 tumors.Conclusions. Several studies have reported outcomes in patients with recurrent meningiomas testing a variety ofagents with modest, but variable and progressively increasing activity. In this context, we recommend new benchmarksfor future trials to define efficacy of future investigational therapies. |
| 536 | _ | _ | |a 5252 - Brain Dysfunction and Plasticity (POF4-525) |0 G:(DE-HGF)POF4-5252 |c POF4-525 |f POF IV |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef, Journals: juser.fz-juelich.de |
| 700 | 1 | _ | |a Akdemir, Eyub Y |0 0000-0002-6848-4289 |b 1 |
| 700 | 1 | _ | |a Kutuk, Tugce |0 P:(DE-HGF)0 |b 2 |
| 700 | 1 | _ | |a Ilgın, Can |0 P:(DE-HGF)0 |b 3 |
| 700 | 1 | _ | |a Ahluwalia, Manmeet S |0 P:(DE-HGF)0 |b 4 |
| 700 | 1 | _ | |a Bi, Wenya L |0 P:(DE-HGF)0 |b 5 |
| 700 | 1 | _ | |a Blakeley, Jaishri |0 0000-0002-1049-0993 |b 6 |
| 700 | 1 | _ | |a Dixit, Karan S |0 P:(DE-HGF)0 |b 7 |
| 700 | 1 | _ | |a Dunn, Ian F |0 P:(DE-HGF)0 |b 8 |
| 700 | 1 | _ | |a Galanis, Evanthia |0 0000-0001-8014-786X |b 9 |
| 700 | 1 | _ | |a Galldiks, Norbert |0 P:(DE-Juel1)143792 |b 10 |
| 700 | 1 | _ | |a Huang, Raymond Y |0 P:(DE-HGF)0 |b 11 |
| 700 | 1 | _ | |a Johnson, Derek R |0 P:(DE-HGF)0 |b 12 |
| 700 | 1 | _ | |a Kaley, Thomas J |0 P:(DE-HGF)0 |b 13 |
| 700 | 1 | _ | |a Kamson, David O |0 P:(DE-HGF)0 |b 14 |
| 700 | 1 | _ | |a Kurz, Sylvia C |0 P:(DE-HGF)0 |b 15 |
| 700 | 1 | _ | |a McDermott, Michael W |0 P:(DE-HGF)0 |b 16 |
| 700 | 1 | _ | |a Odia, Yazmin |0 P:(DE-HGF)0 |b 17 |
| 700 | 1 | _ | |a Preusser, Matthias |0 P:(DE-HGF)0 |b 18 |
| 700 | 1 | _ | |a Raizer, Jeffrey |0 P:(DE-HGF)0 |b 19 |
| 700 | 1 | _ | |a Reardon, David A |0 P:(DE-HGF)0 |b 20 |
| 700 | 1 | _ | |a Rogers, C Leland |0 P:(DE-HGF)0 |b 21 |
| 700 | 1 | _ | |a Ruda, Roberta |0 P:(DE-HGF)0 |b 22 |
| 700 | 1 | _ | |a Schiff, David |0 P:(DE-HGF)0 |b 23 |
| 700 | 1 | _ | |a Vogelbaum, Michael A |0 P:(DE-HGF)0 |b 24 |
| 700 | 1 | _ | |a Weller, Michael |0 0000-0002-1748-174X |b 25 |
| 700 | 1 | _ | |a Wen, Patrick Y |0 0000-0002-0774-7700 |b 26 |
| 700 | 1 | _ | |a Mehta, Minesh P |0 P:(DE-HGF)0 |b 27 |
| 773 | _ | _ | |a 10.1093/neuonc/noaf009 |g Vol. 27, no. 7, p. 1670 - 1685 |0 PERI:(DE-600)2094060-9 |n 7 |p 1670 - 1685 |t Neuro-Oncology |v 27 |y 2025 |x 1522-8517 |
| 856 | 4 | _ | |u https://juser.fz-juelich.de/record/1052252/files/noaf009.pdf |y OpenAccess |
| 909 | C | O | |o oai:juser.fz-juelich.de:1052252 |p openaire |p open_access |p VDB |p driver |p dnbdelivery |
| 910 | 1 | _ | |a Forschungszentrum Jülich |0 I:(DE-588b)5008462-8 |k FZJ |b 10 |6 P:(DE-Juel1)143792 |
| 913 | 1 | _ | |a DE-HGF |b Key Technologies |l Natural, Artificial and Cognitive Information Processing |1 G:(DE-HGF)POF4-520 |0 G:(DE-HGF)POF4-525 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-500 |4 G:(DE-HGF)POF |v Decoding Brain Organization and Dysfunction |9 G:(DE-HGF)POF4-5252 |x 0 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2024-12-11 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2024-12-11 |
| 915 | _ | _ | |a IF >= 15 |0 StatID:(DE-HGF)9915 |2 StatID |b NEURO-ONCOLOGY : 2022 |d 2024-12-11 |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b NEURO-ONCOLOGY : 2022 |d 2024-12-11 |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0113 |2 StatID |b Science Citation Index Expanded |d 2024-12-11 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2024-12-11 |
| 915 | _ | _ | |a OpenAccess |0 StatID:(DE-HGF)0510 |2 StatID |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0160 |2 StatID |b Essential Science Indicators |d 2024-12-11 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1110 |2 StatID |b Current Contents - Clinical Medicine |d 2024-12-11 |
| 915 | _ | _ | |a Nationallizenz |0 StatID:(DE-HGF)0420 |2 StatID |d 2024-12-11 |w ger |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2024-12-11 |
| 920 | _ | _ | |l yes |
| 920 | 1 | _ | |0 I:(DE-Juel1)INM-3-20090406 |k INM-3 |l Kognitive Neurowissenschaften |x 0 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a UNRESTRICTED |
| 980 | _ | _ | |a I:(DE-Juel1)INM-3-20090406 |
| 980 | 1 | _ | |a FullTexts |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|
guest ::